Table 2.

Effect of ZnO NPs on serum lipid profile and liver markers

	Group I (control)	Group II (diabetic control)	Group III (positive control – glibenclamide)	Group IV (ZnO NPs 5 mg/kg b.wt)	Group V (ZnO NPs 10 mg/kg b.wt)
TC (mg/dl)	188.28 ± 17.60	434.64 ± 29.41 a**	153.65 ± 19.86 b**	177.86 ± 26.64 b**	145.83 ± 10.83 b**
triglycerides (mg/dl)	267.52 ± 2.61	293.66 ± 4.35 a**	255.16 ± 5.35 b**	274.58 ± 3.78 b*	254.77 ± 1.64 b**
LDL (mg/dl)	47.71 ± 15.25	258.17 ± 30.60 a**	36.24 ± 15.86 b**	43.80 ± 19.65 b**	21.81 ± 3.61 b**
HDL (mg/dl)	87.07 ± 9.16	117.73 ± 2.84	66.37 ± 6.70 b**	79.15 ± 11.20 b*	73.07 ± 11.39 b*
ALT (IU/l)	40.96 ± 5.09	77.50 ± 3.53 a*	58.05 ± 8.92	47.44 ± 3.61 b**	48.47 ± 4.49 b*
AST (IU/l)	58.79 ± 6.38	91.49 ± 5.39 a*	54.96 ± 13.23	52.89 ± 6.72	69.54 ± 5.27

Values are mean±SEM, n  = 6, *p  < 0.05, **p  < 0.01. Statistical analysis – ANOVA followed by Tukey's comparison test. a: comparison of group I with other groups and b: comparison of group II with other groups.